Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia Polycythemia Vera Myelofibrosis

被引：14
|
作者：
Verstovsek, Srdan [1 ]
Odenike, Olatoyosi [2 ]
Scott, Bart [3 ]
Estrov, Zeev [1 ]
Cortes, Jorge [1 ]
Thomas, Deborah A. [1 ]
Wood, Jeanette [4 ]
Ethirajulu, Kantharaj [4 ]
Lowe, Ann [4 ]
Zhu, Huan J. [4 ]
Kantarjian, Hagop [1 ]
Deeg, H. Joachim [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[4] S BIO PTE LTD, Singapore, Singapore
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
10.1182/blood.V114.22.3905.3905
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1502 / 1502
页数：1
相关论文
共 21 条
  • [1] Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis
    Komrokji, Rami S.
    Wadleigh, Martha
    Seymour, John F.
    Roberts, Andrew W.
    To, Luen Bik
    Zhu, Huan J.
    Mesa, Ruben A.
    BLOOD, 2011, 118 (21) : 130 - 131
  • [2] Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis
    Verstovsek, Srdan
    Deeg, H. Joachim
    Odenike, Olatoyosi
    Zhu, Joy
    Kantarjian, Hagop
    Estrov, Zeev
    Scott, Bart Lee
    Thomas, Deborah A.
    BLOOD, 2010, 116 (21) : 1271 - 1271
  • [3] SB1518, a novel JAK2/FLT3 inhibitor for the treatment of myeloid malignancies
    Hart, Stefan
    Goh, Kee Chuan
    Novotny-Diermayr, Veronica Veronica
    Tan, Yong Cheng
    Madan, Babita
    Amalini, Chithra
    Loh, Yung Kiang
    Ong, Lai Chun
    Williams, Anthony
    Lee, Angeline
    Poulsen, Anders
    Jayaraman, Ramesh
    Ethirajulu, Kantharaj
    Dymock, Brian W.
    Wood, Jeanette M.
    CANCER RESEARCH, 2011, 71
  • [4] Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
    Hart, S.
    Goh, K. C.
    Novotny-Diermayr, V.
    Tan, Y. C.
    Madan, B.
    Amalini, C.
    Ong, L. C.
    Kheng, B.
    Cheong, A.
    Zhou, J.
    Chng, W. J.
    Wood, J. M.
    BLOOD CANCER JOURNAL, 2011, 1 : e44 - e44
  • [5] Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
    S Hart
    K C Goh
    V Novotny-Diermayr
    Y C Tan
    B Madan
    C Amalini
    L C Ong
    B Kheng
    A Cheong
    J Zhou
    W J Chng
    J M Wood
    Blood Cancer Journal, 2011, 1 : e44 - e44
  • [6] A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
    Shah, Neil P.
    Olszynski, Patrycja
    Sokol, Lubomir
    Verstovsek, Srdan
    Hoffman, Ronald
    List, Alan F.
    Cortes, Jorge
    Kantadian, Hagop M.
    Gilliland, D. Gary
    Clary, Douglas O.
    Bui, Lynne A.
    Wadleigh, Martha
    BLOOD, 2008, 112 (11) : 44 - 44
  • [7] Design, synthesis and SAR studies leading to SB1518, a novel macrocyclic JAK2/FLT3 inhibitor in phase 2 clinical trials for myelofibrosis and lymphoma
    Lee, Angeline
    William, Anthony
    Poulsen, Anders
    Tan, Evelyn
    Nagaraj, Harish
    Goh, Kay Lin
    Ong, Wai Chung
    Goh, Kee Chuan
    Pasha, Mohammed Khalid
    Jayaraman, Ramesh
    Ethirajulu, Kantharaj
    Wood, Jeanette M.
    Dymock, Brian W.
    CANCER RESEARCH, 2011, 71
  • [8] CHARACTERIZATION OF THE PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF PACRITINIB (SB1518), A NOVEL ORAL JAK2/FLT3 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS, AML AND LYMPHOMA
    Al-Fayoumi, S.
    Wang, L.
    Dean, J.
    Benner, S.
    HAEMATOLOGICA, 2013, 98 : 406 - 406
  • [9] PHASE II STUDY OF CEP-701, AN ORALLY AVAILABLE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
    Santos, F. P. S.
    Kantarjian, H.
    Jain, N.
    Thomas, D.
    Garcia-Manero, G.
    Cortes, J.
    Verstovsek, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 439 - 439
  • [10] Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen K.
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady
    Rivera, Candido E.
    Uno, Tomonori
    Mesa, Ruben A.
    BLOOD, 2016, 128 (22)
123